We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $281M
1-Year Est. Return 261.03%
This Fund
S&P 500
This Quarter Est. Return
-20.59%
1 Year Est. Return
+261.03%
3 Year Est. Return
+648.19%
5 Year Est. Return
+623.84%
10 Year Est. Return
–
AUM
$124M
AUM Growth
-$47.2M
Cap. Flow
-$3.53M
Cap. Flow %
-2.85%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
2
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$1.79M
2
ARTV
Artiva Biotherapeutics
ARTV
+$1.73M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.39B
$67.3M 54.5%
4,289,304
– –
ALMS
2
Alumis Inc
ALMS
$3.57B
$17.1M 13.85%
2,787,398
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.04B
$16.2M 13.14%
489,194
-50,000
-9% -$1.79M
SLRN
4
DELISTED
ACELYRIN
SLRN
$9.4M 7.61%
3,806,410
– –
ALXO icon
5
ALX Oncology
ALXO
$275M
$6.04M 4.89%
9,699,925
– –
LYEL icon
6
Lyell Immunopharma
LYEL
$309M
$3.82M 3.09%
355,110
– –
ARTV
7
Artiva Biotherapeutics
ARTV
$489M
$3.6M 2.91%
1,198,975
-320,996
-21% -$1.73M

Similar funds

FFP
Freedom Financial Partners Oakdale, Minnesota $281M AUM 16.89% 1-Year Est. Return
BDA
Borer Denton & Associates Blue Bell, Pennsylvania $280M AUM 7.09% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
SA
SoundView Advisors Olympia, Washington $281M AUM 17.96% 1-Year Est. Return
ACC
Acorn Creek Capital Fort Collins, Colorado $280M AUM 19.97% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $281M AUM 56.22% 1-Year Est. Return
IP
Investment Partners New Philadelphia, Ohio $281M AUM 20.9% 1-Year Est. Return

venBio Partners's Q1 2025 Portfolio in Review

As of Q1 2025, venBio Partners held 7 positions worth $124M, down 28% from $171M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2025: portfolio turnover was 0%. venBio Partners opened no new positions and made no exits, leaving the 7-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners's biggest Q1 2025 reduction was Harmony Biosciences, cutting an estimated $1.79M.
  • venBio Partners's ten largest holdings make up 100% of its $124M portfolio in Q1 2025.
  • venBio Partners opened 0 new positions and closed 0 in Q1 2025.
  • venBio Partners's portfolio value fell 28% quarter-over-quarter to $124M.

Based on venBio Partners's 13F filing for Q1 2025, filed 15 May 2025.